Data Sheet (Cat.No.T12876)

TargetMol

Seladelpar sodium salt

Chemical Properties



CAS No. : 2751530-13-7

Formula: C21H22F3NaO5S

Molecular Weight: 466.45

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	Seladelpar sodium salt (MBX-8025) is an orally active and specific PPARδ agonist with an EC50 of 2 nM, demonstrating over 750-fold and 2500-fold selectivity compared to the PPARα and PPARγ receptors, respectively.
Targets(IC50)	Others
In vitro	MBX-8025 is an orally active, potent (EC50 = 2 nM) PPARδ agonist, exhibiting 750-fold and 2500-fold higher specificity compared to PPARα and PPARγ receptors, respectively, and is being developed as a lipid-altering agent [2] [3].
In vivo	In a study involving Wt mice on an atherogenic diet, Seladelpar sodium salt administration led to a significant reduction of approximately 18% in body weight (P<0.05), whereas its impact on foz/foz mice under the same diet was minimal. Additionally, this compound significantly lowered serum alanine aminotransferase (ALT) levels in foz/foz mice (P<0.05) and exhibited a similar, though not significant, effect in Wt mice. Seladelpar sodium salt was effective in normalizing serum cholesterol levels and reducing triglycerides across both mouse genotypes (P<0.05). It also eliminated hepatocyte ballooning (P<0.05) and halved the nonalcoholic fatty liver disease (NAFLD) activity score by approximately 50%. Moreover, the compound notably diminished sirius red-positive areas in foz/foz mice (P<0.05) [4].

Solubility Information

Solubility	DMSO: 50 mg/mL (107.19 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1439 mL	10.7193 mL	21.4385 mL
5 mM	0.4288 mL	2.1439 mL	4.2877 mL
10 mM	0.2144 mL	1.0719 mL	2.1439 mL
50 mM	0.0429 mL	0.2144 mL	0.4288 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Sahebkar A, et al. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother. 2014 Mar;15(4):493-503.
Bays HE, et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab. 2011 Sep;96(9):2889-97.
Choi YJ, et al. Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia. Atherosclerosis. 2012 Feb;220(2):470-6.
Haczeyni F, et al. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. Hepatol Commun. 2017 Jul 31;1(7):663-674.